BRANFORD, Conn.--(BUSINESS WIRE)--454 Life Sciences, a Roche Company (SWX:RO) (SWX:ROG) (Pink Sheets: RHHBY), announced today at the Association of Molecular Pathology Annual Meeting in Kissimmee, Florida a series of revolutionary developments which significantly expand the company’s high-throughput sequencing portfolio. Addressing the growing demand for next-generation sequencing data in everyday biological and clinical research, the company revealed the new GS Junior System, an affordable bench top sequencing platform slated for release in 2010.